#1 Clinical Trials Search in Europe

Study on Extending Osimertinib Dosing for Patients with EGFR Mutated Advanced Non-Small Cell Lung Cancer

1 1 1 1

What is this study about?

This clinical trial is focused on studying a type of lung cancer known as . This form of cancer involves changes in the epidermal growth factor receptor (EGFR) gene, which can lead to the growth and spread of cancer cells. The treatment being investigated in this study is a medication called , which is also known by its code name . Osimertinib is taken in the form of and is used to target and treat this specific type of lung cancer.

The purpose of the study is to assess whether extending the time between doses of osimertinib is as effective as the current standard dosing schedule. Participants in the study will receive osimertinib and will be monitored over time to see how their cancer responds to the treatment. The study will look at various outcomes, including how long patients live without their cancer getting worse, overall survival, and the impact on quality of life. Additionally, the study will evaluate the occurrence of any side effects and how well patients adhere to the medication schedule.

Throughout the study, researchers will also consider factors such as the economic impact of the treatment and the incidence of cancer spreading to the brain, known as . The trial aims to provide valuable information on whether a less frequent dosing schedule can maintain the effectiveness of osimertinib while potentially improving the overall treatment experience for patients with this type of lung cancer.

1 beginning of the trial

Upon joining the clinical trial, you will start by taking the medication osimertinib. This medication is provided in the form of TAGRISSO 80 mg film-coated tablets.

You will take one tablet orally every day. This is referred to as taking the medication once daily.

2 treatment phase

During the treatment phase, you will continue taking the osimertinib tablet daily. The trial aims to assess if extending the time between doses is as effective as the standard daily dosage.

Regular check-ups will be scheduled to monitor your health and the effectiveness of the treatment. These check-ups will include assessments of your response to the medication.

3 monitoring and assessments

Throughout the trial, your health will be closely monitored. This includes evaluating your progression-free survival, which means the length of time during and after the treatment that you live with the disease without it getting worse.

Additional assessments will focus on your overall survival, any side effects you experience, and your quality of life. These assessments help determine the impact of the treatment on your daily life.

4 end of trial participation

Your participation in the trial will continue until the trial’s estimated end date or until your doctor advises otherwise based on your health and response to the treatment.

At the end of your participation, a final assessment will be conducted to evaluate the overall outcomes of the treatment and its effects on your health.

Who Can Join the Study?

  • Age must be 18 years or older.
  • Must be able to understand the written information and give informed consent, which means agreeing to participate after understanding the details of the study.
  • Must have enough knowledge of the local language to answer the questionnaires.
  • Must have locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific genetic changes called EGFR exon 19 deletions or exon 21 L858R mutations. These are specific changes in the cancer cells that affect how they grow.
  • Must not be eligible for treatments aimed at curing the cancer.
  • Must have been treated with a medication called osimertinib at a dose of 80 mg once a day, with or without chemotherapy, for at least three months as part of standard care.
  • Must have shown a response to treatment based on radiologic assessment. This means that scans or images show that the cancer has either completely or partially responded to treatment, as judged by the doctor.

Who Cannot Join the Study?

  • Patients with any other type of cancer besides EGFR mutated locally advanced or metastatic non-small cell lung cancer cannot participate. EGFR is a protein that helps cells grow and divide. When it is mutated, it can cause cancer.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are part of a vulnerable population, such as those unable to give consent, cannot participate.
  • Patients who are not able to follow the study procedures or take the study medication as required cannot participate.
  • Patients who have any medical condition that the study doctors believe would make it unsafe for them to participate cannot join the study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
University Hospital Maastricht Maastricht The Netherlands

Other Sites

Site Name City Country Status
Universitair Medisch Centrum Utrecht Utrecht The Netherlands
Sfhrqqlmf Rvlnbcr Uwgplgiaug Mxtizdu Cerypc Nijmegen The Netherlands
Etbgxtb Umquicgxtidz Mninoez Cvthscm Rsszmjnpb (ezzsxmy Mmd Rotterdam The Netherlands
Afpeooxwf Uih Amsterdam The Netherlands
Lumbd Uotposwudvuk Mllsooe Cyyibyp (ericn Leiden The Netherlands
Uxnqyqlwfycx Mkblwhf Chbmdeu Gynzlsysk Groningen The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Not yet recruiting
01.05.2025

Trial locations

Investigated drugs:

Osimertinib is a medication used to treat a specific type of lung cancer known as non-small cell lung cancer (NSCLC) that has certain mutations in the EGFR gene. It works by blocking the activity of the EGFR protein, which is involved in the growth and spread of cancer cells. In this clinical trial, researchers are studying whether taking osimertinib less frequently is as effective as the standard daily dosage. This could potentially make the treatment more convenient for patients while maintaining its effectiveness in controlling cancer growth.

Investigated diseases:

EGFR mutated locally advanced or metastatic non-small cell lung cancer – This type of lung cancer is characterized by mutations in the epidermal growth factor receptor (EGFR) gene, which leads to uncontrolled cell growth. It is classified as non-small cell lung cancer, which is the most common type of lung cancer. The disease can be locally advanced, meaning it has spread to nearby tissues or lymph nodes, or metastatic, indicating it has spread to other parts of the body. The progression involves the cancer cells growing and potentially spreading to other organs, which can affect their function. Symptoms may include persistent cough, chest pain, and difficulty breathing. As the disease advances, it may lead to further complications depending on the organs affected by metastasis.

Trial ID:
2024-514693-47-00
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • Testing the Safety and Effects of TUB-030 in Patients with Advanced Head and Neck Cancer or Non-Small-Cell Lung Cancer

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Romania Spain

  • Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Estonia France Germany Ireland Italy +1